From Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert

Similar documents
PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019

PCSK9 Inhibition: From Genetics to Patients

New Horizons in Dyslipidemia Management in Primary Care

Familial Hypercholesterolemia What a cardiologist should know

INTERNAL MEDICINE - PEDIATRICS

HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary

Hypercholesterolaemia is there a place for PCSK9-inhibitor therapy?

*Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa

PCSK9 Inhibitors: Promise or Pitfall?

DIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO

Repatha. Repatha (evolocumab) Description

Lipid Metabolism in Familial Hypercholesterolemia

Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges

Repatha. Repatha (evolocumab) Description

Cholesterol, guidelines, targets and new medications

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description

Management of Dyslipidaemias: PCSK9 Inhibition. Alberico L. Catapano Professor President EAS University of Milano Italy

Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013

PCSK9 and its Inhibitors Past, Present, and Future Implications

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool

Familial Hypercholeterolaemia

Inhibition of PCSK9: The Birth of a New Therapy

Familial hypercholesterolaemia

PCSK9 inhibition in familial hypercholesterolemia: A revolution in treatment

Juxtapid. Juxtapid (lomitapide) Description

PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia

Drug Class Prior Authorization Criteria PCSK9 Inhibitors

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017

UNIVERSITA DI PISA CHIMICA E TECNOLOGIE FARMACEUTICHE FAMILIAL HYPERCHOLESTEROLEMIA DIPARTIMENTO DI FARMACIA GENETIC CAUSES AND THERAPY

Genetic Dyslipidemia and Cardiovascular Diseases

Beyond HDL: new therapeutic targets

Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies

PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

PCSK9 inhibition in homozygous familial hypercholesterolaemia

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?

Novel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27

Kynamro. Kynamro (mipomersen) Description

PCSK9 Inhibitors Current Status

See Important Reminder at the end of this policy for important regulatory and legal information.

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Cholesterol Synthesis and Absorption Markers

See Important Reminder at the end of this policy for important regulatory and legal information.

LIPID CLUB Rome, 2014

Drug Prior Authorization Guideline PCSK9 Inhibitors -

Juxtapid (lomitapide)

Pharmacy Policy Bulletin

PCSK9 Inhibitors Current Status

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017

Educational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Genetic considerations in the treatment of familial hypercholesterolemia

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Nephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler

Presenter Disclosure Information

Drug Class Monograph

Evaluating Residual Risk and Long-term Management of the Young CHD Patient. The Arterial Wall

Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

New Drugs and Technologies

Le Dislipidemie familiari nell età pediatrica: quale approccio? O. GUARDAMAGNA di Scienze della Sanità pubblica e pediatriche

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:

The Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia

PCSK9 Agents Drug Class Prior Authorization Protocol

Antisense and Antibodies as Game changers in refractory dyslipidemia. Erik Stroes AMC

WORKSHOP 1. Management of Patients with Familial Hypercholesterolemia

Whats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i?

Lipids: new drugs, new trials, new guidelines

Kynamro. Kynamro (mipomersen) Description

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Hypercholesterolemia: So much cholesterol, so many causes

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis

PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab)

Treating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC

Metabolism and Atherogenic Properties of LDL

PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors

Supplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Screening for dyslipidemias in children and adolescents

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

ADMINISTRATIVE POLICY AND PROCEDURE

PCSK9 Inhibitors: A View of Clinical Studies

Summary of the risk management plan (RMP) for Praluent (Alirocumab)

QUANTITY LIMIT TARGET DRUGS- RECOMMENDED LIMITS Brand (generic) GPI Multisource Code Quantity Limit

ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results

Treatment of severe Familial Hypercholesterolemia LDL Apheresis

PCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION

DYSLIPIDEMIA. Michael Brändle, Stefan Bilz

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection

Early Clinical Development #1 REGN727: anti-pcsk9

Treatment of severe Familial Hypercholesterolemia PCSK9 inhibitors

THE LATEST IN CARDIOVASCULAR RISK LIPID MANAGEMENT

Transcription:

Dr. Gilles Lambert Associate Professor in Cell Biology University of Nantes Medical School Group Leader, Laboratory of Nutrition and Metabolism, University Hospital of Nantes From Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th

PCSK9: The Enzyme Proprotein Convertase Subtilisin Kexin type 9 Endoplasmic Reticulum D H N S pro-domain catalytic domain C-terminal domain Golgi D H N S catalytic domain C-terminal domain pro-domain Secretion Lambert et al. (2009) Atherosclerosis

PCSK9: The Chaperone (Binds to the LDLR) PCSK9 Catalytic domain EGFA domain LDLR CHRD Prodomain Endocytosis Seidah et al. (2014) Circ Res

+ PCSK9 PCSK9 Targets the LDLR to the Lysosome for Degradation LDLR Endosome Merge PCSK9-LDLR Binding LDLR Conformation Kd=750±80nM (at ph 7,5) Open (at ph 7,5) Kd= 10±1nM (at ph 5,5) Closed (at ph 5,5) alone Open (at ph5,5) bound to PCSK9 Surdo et al. (2011) EMBO Reports

PCSK9 Reduces LDLR Cell Surface Expression Dose Dependently MFI: median fluorescence intensity * p<0,05, ** p<0,01 vs. condition no PCSK9 (0) Lambert et al. (2014) J Am Coll Cardiol

PCSK9: A Natural Inhibitor of the LDL Receptor Lambert et al. (2012) J. Lipid Res.

Mean PCSK9 (ng/ml) Statins Increase Circulating PCSK9 Levels in cohorts 400 350 * 345 ** 352 ** 365 328 300 250 Atorva 10 (n=449) Atorva 20 (n=449) Atorva 40 (n=447) Atorva 80 (n=399) Atorvastatin Dose * p<0,01 vs. 10mg, ** p<0,01 vs. 10, 20mg Lambert G. Unpublished data.

Emerging Therapy: PCSK9 Inhibitors mab Lambert et al. (2012) J. Lipid Res.

PCSK9 in Brief: PCSK9 is a natural circulating inhibitor of the LDLR that targets the receptor for degradation following endocytosis. PCSK9 and LDLR genes are co-regulated by intracellular cholesterol content and statin treatment. Targeting plasma PCSK9 is conceptually a promising approach to lower LDL-C levels in monotherapy as well as on top of statins.

FH : Four monogenic disorders 90% 5% <1% <1%

(1a)- PCSK9 modulates the FH phenotype Normolipemic Individuals Heterozygous FH patient (Prevalence 1/250) Homozygous FH patient (Prevalence 1/300.000)

Clinical characteristics * p<0.01 vs. controls Lambert et al. (2014) J Am Coll Cardiol

Correlation Studies

Mechanistic Studies Control WT/WT FH patient WT/D206E FH patient WT/V408M FH patient WT/D154N SKIN FIBROBLASTS 20% FCS 0.5% FCS 0.5% FCS + mevastatin 10ug/mL 0.5% FCS + mevastatin 20ug/mL 0.5% FCS + mevastatin 40ug/mL rpcsk9 (0, 150, 300 or 600 ng/ml) LDLr Expression by FC

PCSK9 Similarly Reduces LDLR Cell Surface Expression in non-fh and HeFH fibroblasts.

PCSK9 levels are increased in asymptomatic FH patients with coronary artery calcifications

(1a)- PCSK9 in Heterozygote FH patients Elevated circulating PCSK9 levels aggravate the hypercholesterolemic phenotype of heterozygous FH patients. Elevated circulating PCSK9 is an independent predictor of coronary arteries calcifications in heterozygote FH patients.

(1b)- PCSK9 in Homozygote FH Normolipemic Individuals Heterozygous FH patient (Prevalence 1/250) Homozygous FH patient (Prevalence 1/300.000) LDLR defective LDLR negative

Statins modulate LDLR expression in HoFH Defective but not in HoFH Negative Fibroblasts Non-FH HeFH HoFH null HoFH defective 20% FCS 0.5% FCS 10 20 40 WT 700 Isotype Isotype 20% FCS 20% FCS 0,5% FCS 0,5% FCS Mevastatin 10 Mevastatin 10 Mevastatin 20 Mevastatin 20 Mevastatin 40 Mevastatin 40 0 2000 4000 6000 MFI (Median) 0 2000 4000 6000 MFI (Median)

PCSK9 modulate LDLR expression in HoFH Defective but not in HoFH Negative Fibroblasts Lambert et al. (2014) J Am Coll Cardiol

(1b)- PCSK9 in Homozygote FH Statins increase whereas PCSK9 reduces LDLR cell surface expression in controls, heterozygote FH and homozygote FH cells carrying at least one receptor defective LDLR allele but not in those isolated from carriers of two receptor negative LDLR alleles. PCSK9 inhibition will reduce LDL-C levels in all HeFH irrespective of their mutation status and in the majority of HoFH patients.

(2)- PCSK9 in Autosomal Recessive Hypercholesterolemia (ARH) ADH LBD ARH 90% 5% < 1% Homozygous FH LDLR (n=42) ARH (n=42) TC (mmol/l) LDLC (mmol/l) 18.4 ± 3.6 16.3 ± 2.5 16.9 ± 3.5 14.6 ± 2.4

LDLR expression in ARH lymphocytes

LDL uptake in ARH lymphocytes

(2)- PCSK9 in Autosomal Recessive Hypercholesterolemia (ARH) Statins increase whereas PCSK9 reduces LDLR cell surface expression in lymphocytes isolated from control and ARH patients. Cellular LDL uptake is increased by statin treatment and reduced by PCSK9 and increased back to baseline levels by the PCSK9i Alirocumab in ARH lymphocytes but to much lower extents than in control cells. These in vitro findings suggest that PCSK9 inhibition may potentially reduce LDL-C in ARH patients currently treated with statins and LDL apheresis.

(3)- PCSK9 in Autosomal Dominant Hypercholesterolemia 3

PCSK9 inhibition for PCSK9 GOF FH patients

(3)- PCSK9 inhibition with mabs for FH patients to reduce LDL-C ADH1 : All heterozygotes (irrespective of their LDLR mutation status) ADH1 : Most homozygotes (carrying at least one LDLR defective allele) ADH2 (LDB) : Not known but likely to work for HeFH and HoFH LDB. ARH : Cellular resistance to statins and PCSK9, but worth to test in patients. ADH3 (PCSK9 GOF) : Likely to work for all PCSK9 GOF mutations carriers.

(4)- Not just LDL-C also Lp(a) PCSK9 inhibition by monoclonal antibody therapy was shown to be very effective at reducing circulating LDL-C and, by unexplained mechanisms, to decrease Lp(a) plasma levels. PCSK9 effects on apo(a)/lp(a) levels synthesis in human primary hepatocytes PCSK9 effects on Lp(a) cellular catabolism in primary hepatocytes and dermal fibroblasts

Not just LDL also Lp(a) PCSK9 increased Lp(a) levels in cell media PCSK9 increased apo(a) gene expression

PCSK9 did not modify Lp(a)-bodipy uptake in hepatocytes

PCSK9 did not modify Lp(a)-bodipy uptake in fibroblasts Plasma Lp(a) decrease associated with PCSK9 inhibition in clinical trials may result primarily from impaired Lp(a) production

CONCLUSIONS PCSK9 is a natural circulating inhibitor of the LDLR that targets the receptor for degradation following endocytosis. Targeting plasma PCSK9 is conceptually a promising approach to lower LDL-C levels particularly for FH patients (HeFH, receptor defective HoFH, PCSK9 GOF, and maybe some ARH patients) PCSK9 modulates LDL-C levels via a functional LDLR pathway (requiring ARH). Our in vitro data suggest that PCSK9 may not modulate Lp(a) levels through the same cellular mechanism but rather by impacting Lp(a) production.